{"id":59578,"date":"2026-03-16T14:14:07","date_gmt":"2026-03-16T06:14:07","guid":{"rendered":"https:\/\/flcube.com\/?p=59578"},"modified":"2026-03-16T14:14:07","modified_gmt":"2026-03-16T06:14:07","slug":"bebetter-medicines-ifupinostat-wins-nmpa-approval-for-ptcl-trial-first-hdac-pi3k%ce%b1-dual-inhibitor-enters-first-line-lymphoma-study","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59578","title":{"rendered":"BeBetter Medicine&#8217;s Ifupinostat Wins NMPA Approval for PTCL Trial \u2013 First HDAC\/PI3K\u03b1 Dual Inhibitor Enters First-Line Lymphoma Study"},"content":{"rendered":"\n<p><strong>Guangzhou BeBetter Medicine Technology Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688759:SHA\">SHA: 688759<\/a>) announced <strong>NMPA clearance<\/strong> to initiate a <strong>clinical study<\/strong> evaluating <strong>ifupinostat (BEBT-908)<\/strong> in <strong>combination with CHOP regimen<\/strong> for <strong>newly diagnosed peripheral T-cell lymphoma (PTCL)<\/strong>. The <strong>world&#8217;s first approved HDAC\/PI3K\u03b1 dual-target inhibitor<\/strong>, which received <strong>conditional NMPA approval in June 2025 for relapsed\/refractory DLBCL<\/strong>, now expands into <strong>first-line T-cell lymphoma<\/strong> with a <strong>chemo-immunotherapy backbone<\/strong>, leveraging its <strong>synergistic dual blockade mechanism<\/strong> to address a <strong>high-unmet-need malignancy<\/strong> with limited standard-of-care options.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial authorization (IND)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Ifupinostat (BEBT-908)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>HDAC\/PI3K\u03b1 dual-target inhibitor \u2013 <strong>world&#8217;s first approved<\/strong><\/td><\/tr><tr><td><strong>Combination<\/strong><\/td><td>CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Newly diagnosed peripheral T-cell lymphoma (PTCL)<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Guangzhou BeBetter Medicine Technology (SHA: 688759)<\/td><\/tr><tr><td><strong>Prior Approval<\/strong><\/td><td>Conditional NMPA approval (June 2025) \u2013 r\/r DLBCL monotherapy<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>16\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Ifupinostat (BEBT-908) Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Dual Targets<\/strong><\/td><td>\u2022 PI3K\u03b1 (phosphatidylinositol 3-kinase alpha) \u2013 core signal transduction kinase<br>\u2022 HDAC (histone deacetylase) \u2013 epigenetic regulator<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Synergistic anti-tumor effect through dual pathway blockade: \u2022 PI3K\u03b1 inhibition: Disrupts tumor cell survival signaling<br>\u2022 HDAC inhibition: Modulates gene expression, induces apoptosis<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Oral administration<\/td><\/tr><tr><td><strong>Approved Indication<\/strong><\/td><td>r\/r DLBCL (conditional, June 2025) \u2013 monotherapy after \u22652 prior therapies<\/td><\/tr><tr><td><strong>Confirmatory Trial<\/strong><\/td><td>Phase III combination with rituximab (second-line+ r\/r DLBCL) \u2013 ongoing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>PTCL Rationale:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Aggressive Disease:<\/strong> PTCL carries poor prognosis; 5-year survival &lt;30% for most subtypes<\/li>\n\n\n\n<li><strong>CHOP Limitations:<\/strong> Standard CHOP achieves only 30-40% complete response; novel combinations needed<\/li>\n\n\n\n<li><strong>Dual-Target Synergy:<\/strong> HDAC\/PI3K blockade addresses T-cell lymphoma biology; potential for enhanced efficacy vs. CHOP alone<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-market-opportunity\">Strategic Context &amp; Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>PTCL Unmet Need<\/strong><\/td><td>China: 10,000+ annual cases; limited targeted therapies; CHOP remains backbone with poor outcomes<\/td><\/tr><tr><td><strong>First-Line Positioning<\/strong><\/td><td>Ifupinostat moves from salvage (r\/r DLBCL) to front-line (PTCL) \u2013 larger addressable population<\/td><\/tr><tr><td><strong>Dual-Mechanism Differentiation<\/strong><\/td><td>Unique HDAC\/PI3K\u03b1 combination vs. single-target competitors (brentuximab, pralatrexate)<\/td><\/tr><tr><td><strong>Conditional Approval Strategy<\/strong><\/td><td>Confirmatory Phase III in DLBCL ongoing; PTCL expansion diversifies clinical risk<\/td><\/tr><tr><td><strong>Pipeline Expansion<\/strong><\/td><td>Potential for additional lymphoma indications (follicular, mantle cell) and solid tumors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Mechanism<\/th><th>PTCL Status<\/th><th>Ifupinostat Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Seattle Genetics\/Takeda<\/strong><\/td><td>Adcetris (brentuximab vedotin)<\/td><td>CD30 ADC<\/td><td>Approved (CD30+ PTCL)<\/td><td>HDAC\/PI3K dual vs. single target; broader applicability (CD30-negative PTCL)<\/td><\/tr><tr><td><strong>Spectrum\/Acrotech<\/strong><\/td><td>Folotyn (pralatrexate)<\/td><td>DHFR inhibitor<\/td><td>Approved (relapsed PTCL)<\/td><td>Oral convenience; dual-mechanism synergy with CHOP<\/td><\/tr><tr><td><strong>Celgene\/BMS<\/strong><\/td><td>Istodax (romidepsin)<\/td><td>HDAC inhibitor<\/td><td>Approved (CTCL, PTCL)<\/td><td>Adds PI3K\u03b1 blockade for enhanced efficacy; combination with CHOP vs. monotherapy<\/td><\/tr><tr><td><strong>BeBetter<\/strong><\/td><td><strong>Ifupinostat<\/strong><\/td><td><strong>HDAC\/PI3K\u03b1 dual inhibitor<\/strong><\/td><td><strong>Phase II-ready (PTCL)<\/strong><\/td><td><strong>First approved dual-target; first-line CHOP combination; oral administration<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-outlook\">Development Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Timeline<\/th><th>Objectives<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase II (PTCL)<\/strong><\/td><td>2026-2028<\/td><td>Efficacy vs. CHOP alone; safety\/tolerability; biomarker identification<\/td><\/tr><tr><td><strong>Phase III (DLBCL confirmatory)<\/strong><\/td><td>2025-2027<\/td><td>Rituximab combination; registrational endpoints; full approval conversion<\/td><\/tr><tr><td><strong>Regulatory Strategy<\/strong><\/td><td>2028-2029<\/td><td>PTCL NDA filing; label expansion to other T-cell lymphomas<\/td><\/tr><tr><td><strong>Global Expansion<\/strong><\/td><td>2027+<\/td><td>U.S.\/EU IND preparation; potential Fast Track for PTCL<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, dual-target mechanism validation, and competitive positioning for ifupinostat in peripheral T-cell lymphoma. Actual results may differ due to combination toxicity, CHOP standard-of-care evolution, and competitive dynamics with novel PTCL therapies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/688759_20260314_PC23.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688759_20260314_PC23.\"><\/object><a id=\"wp-block-file--media-22c80883-dc27-492e-8852-b5d0534e97d4\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/688759_20260314_PC23.pdf\">688759_20260314_PC23<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/688759_20260314_PC23.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-22c80883-dc27-492e-8852-b5d0534e97d4\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Guangzhou BeBetter Medicine Technology Co., Ltd (SHA: 688759) announced NMPA clearance to initiate a clinical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[4200,62,24,4589],"class_list":["post-59578","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-bebetter-medicine-technology","tag-clinical-trial-approval-initiation","tag-rare-orphan-disease-drugs","tag-sha-688759"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BeBetter Medicine&#039;s Ifupinostat Wins NMPA Approval for PTCL Trial \u2013 First HDAC\/PI3K\u03b1 Dual Inhibitor Enters First-Line Lymphoma Study - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Guangzhou BeBetter Medicine Technology Co., Ltd (SHA: 688759) announced NMPA clearance to initiate a clinical study evaluating ifupinostat (BEBT-908) in combination with CHOP regimen for newly diagnosed peripheral T-cell lymphoma (PTCL). The world&#039;s first approved HDAC\/PI3K\u03b1 dual-target inhibitor, which received conditional NMPA approval in June 2025 for relapsed\/refractory DLBCL, now expands into first-line T-cell lymphoma with a chemo-immunotherapy backbone, leveraging its synergistic dual blockade mechanism to address a high-unmet-need malignancy with limited standard-of-care options.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59578\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeBetter Medicine&#039;s Ifupinostat Wins NMPA Approval for PTCL Trial \u2013 First HDAC\/PI3K\u03b1 Dual Inhibitor Enters First-Line Lymphoma Study\" \/>\n<meta property=\"og:description\" content=\"Guangzhou BeBetter Medicine Technology Co., Ltd (SHA: 688759) announced NMPA clearance to initiate a clinical study evaluating ifupinostat (BEBT-908) in combination with CHOP regimen for newly diagnosed peripheral T-cell lymphoma (PTCL). The world&#039;s first approved HDAC\/PI3K\u03b1 dual-target inhibitor, which received conditional NMPA approval in June 2025 for relapsed\/refractory DLBCL, now expands into first-line T-cell lymphoma with a chemo-immunotherapy backbone, leveraging its synergistic dual blockade mechanism to address a high-unmet-need malignancy with limited standard-of-care options.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59578\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-16T06:14:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59578#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59578\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BeBetter Medicine&#8217;s Ifupinostat Wins NMPA Approval for PTCL Trial \u2013 First HDAC\\\/PI3K\u03b1 Dual Inhibitor Enters First-Line Lymphoma Study\",\"datePublished\":\"2026-03-16T06:14:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59578\"},\"wordCount\":539,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"BeBetter Medicine Technology\",\"Clinical trial approval \\\/ initiation\",\"Rare \\\/ orphan disease drugs\",\"SHA: 688759\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59578#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59578\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59578\",\"name\":\"BeBetter Medicine's Ifupinostat Wins NMPA Approval for PTCL Trial \u2013 First HDAC\\\/PI3K\u03b1 Dual Inhibitor Enters First-Line Lymphoma Study - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-16T06:14:07+00:00\",\"description\":\"Guangzhou BeBetter Medicine Technology Co., Ltd (SHA: 688759) announced NMPA clearance to initiate a clinical study evaluating ifupinostat (BEBT-908) in combination with CHOP regimen for newly diagnosed peripheral T-cell lymphoma (PTCL). The world's first approved HDAC\\\/PI3K\u03b1 dual-target inhibitor, which received conditional NMPA approval in June 2025 for relapsed\\\/refractory DLBCL, now expands into first-line T-cell lymphoma with a chemo-immunotherapy backbone, leveraging its synergistic dual blockade mechanism to address a high-unmet-need malignancy with limited standard-of-care options.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59578#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59578\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59578#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeBetter Medicine&#8217;s Ifupinostat Wins NMPA Approval for PTCL Trial \u2013 First HDAC\\\/PI3K\u03b1 Dual Inhibitor Enters First-Line Lymphoma Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeBetter Medicine's Ifupinostat Wins NMPA Approval for PTCL Trial \u2013 First HDAC\/PI3K\u03b1 Dual Inhibitor Enters First-Line Lymphoma Study - Insight, China&#039;s Pharmaceutical Industry","description":"Guangzhou BeBetter Medicine Technology Co., Ltd (SHA: 688759) announced NMPA clearance to initiate a clinical study evaluating ifupinostat (BEBT-908) in combination with CHOP regimen for newly diagnosed peripheral T-cell lymphoma (PTCL). The world's first approved HDAC\/PI3K\u03b1 dual-target inhibitor, which received conditional NMPA approval in June 2025 for relapsed\/refractory DLBCL, now expands into first-line T-cell lymphoma with a chemo-immunotherapy backbone, leveraging its synergistic dual blockade mechanism to address a high-unmet-need malignancy with limited standard-of-care options.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59578","og_locale":"en_US","og_type":"article","og_title":"BeBetter Medicine's Ifupinostat Wins NMPA Approval for PTCL Trial \u2013 First HDAC\/PI3K\u03b1 Dual Inhibitor Enters First-Line Lymphoma Study","og_description":"Guangzhou BeBetter Medicine Technology Co., Ltd (SHA: 688759) announced NMPA clearance to initiate a clinical study evaluating ifupinostat (BEBT-908) in combination with CHOP regimen for newly diagnosed peripheral T-cell lymphoma (PTCL). The world's first approved HDAC\/PI3K\u03b1 dual-target inhibitor, which received conditional NMPA approval in June 2025 for relapsed\/refractory DLBCL, now expands into first-line T-cell lymphoma with a chemo-immunotherapy backbone, leveraging its synergistic dual blockade mechanism to address a high-unmet-need malignancy with limited standard-of-care options.","og_url":"https:\/\/flcube.com\/?p=59578","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-16T06:14:07+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59578#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59578"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BeBetter Medicine&#8217;s Ifupinostat Wins NMPA Approval for PTCL Trial \u2013 First HDAC\/PI3K\u03b1 Dual Inhibitor Enters First-Line Lymphoma Study","datePublished":"2026-03-16T06:14:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59578"},"wordCount":539,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["BeBetter Medicine Technology","Clinical trial approval \/ initiation","Rare \/ orphan disease drugs","SHA: 688759"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59578#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59578","url":"https:\/\/flcube.com\/?p=59578","name":"BeBetter Medicine's Ifupinostat Wins NMPA Approval for PTCL Trial \u2013 First HDAC\/PI3K\u03b1 Dual Inhibitor Enters First-Line Lymphoma Study - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-16T06:14:07+00:00","description":"Guangzhou BeBetter Medicine Technology Co., Ltd (SHA: 688759) announced NMPA clearance to initiate a clinical study evaluating ifupinostat (BEBT-908) in combination with CHOP regimen for newly diagnosed peripheral T-cell lymphoma (PTCL). The world's first approved HDAC\/PI3K\u03b1 dual-target inhibitor, which received conditional NMPA approval in June 2025 for relapsed\/refractory DLBCL, now expands into first-line T-cell lymphoma with a chemo-immunotherapy backbone, leveraging its synergistic dual blockade mechanism to address a high-unmet-need malignancy with limited standard-of-care options.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59578#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59578"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59578#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BeBetter Medicine&#8217;s Ifupinostat Wins NMPA Approval for PTCL Trial \u2013 First HDAC\/PI3K\u03b1 Dual Inhibitor Enters First-Line Lymphoma Study"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59578","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59578"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59578\/revisions"}],"predecessor-version":[{"id":59581,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59578\/revisions\/59581"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59578"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59578"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59578"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}